Can thinking and walking at the same time predict falls in cancer survivors?
NCT ID NCT06313359
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looks at how nerve damage from cancer treatment affects a person's risk of falling and their quality of life. Researchers will test balance, thinking, and the ability to do two things at once (like walking while texting) in 40 adults with chemotherapy-related peripheral neuropathy. The goal is to understand which factors most strongly predict falls, so better prevention programs can be developed.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could help identify key factors that increase fall risk in cancer survivors, leading to better fall prevention strategies.
- What could go wrong
- This is a small observational study (40 participants) that measures associations, not a treatment trial. Results may not apply to all cancer survivors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 40 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2024
- Expected to finish
-
Jun 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Non CNS Cancer population with neuropathy symptoms related to cancer treatments.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Experimental group * Individuals 18 years and older * diagnosed with non- CNS cancer who underwent treatment and presents with peripheral neuropathy symptoms. Control group * age (+/- one year) and gender matched individuals * no diagnosed peripheral neuropathy * No diagnosed cognitive symptoms. Exclusion Criteria: * Unable to follow two step commands. * Unable to ambulate x 50 feet independently without use of an assistive device. * Unable to use a phone to send text messages. * Diagnosis of diabetic peripheral neuropathy * Diagnosis of CNS cancer. * Unable to speak/understand English
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chemotherapy-induced peripheral neuropathy are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Texas Woman's University
RECRUITINGDallas, Texas, 75235, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can TENS, compression, or cold therapy stop chemo nerve pain?
- Can an antidepressant calm Chemotherapy's nerve pain?
- Retraining the senses to fight chemotherapy nerve damage
- Retraining the senses to fight chemotherapy nerve damage
- Chilling out Chemo's side effects: could cold therapy shield nerves?
- Essential oils vs. chemo nerve pain: a natural remedy put to the test